Panretin is a drug owned by Concordia Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 03, 2016. Details of Panretin's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5932622 | Method for in vivo modulation of non-malignant skin-related processes with 9-cis-retinoic acid |
Aug, 2016
(8 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Panretin is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Panretin's family patents as well as insights into ongoing legal events on those patents.
Panretin's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Panretin's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 03, 2016 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Panretin Generics:
There are no approved generic versions for Panretin as of now.
About Panretin
Panretin is a drug owned by Concordia Pharmaceuticals Inc. It is used for treating cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Panretin uses Alitretinoin as an active ingredient. Panretin was launched by Concordia in 1999.
Approval Date:
Panretin was approved by FDA for market use on 02 February, 1999.
Active Ingredient:
Panretin uses Alitretinoin as the active ingredient. Check out other Drugs and Companies using Alitretinoin ingredient
Treatment:
Panretin is used for treating cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.
Dosage:
Panretin is available in gel form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 0.1% BASE | GEL | Prescription | TOPICAL |